Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
W P Yong, B C Goh, R A Soo, et al.
The American Journal of Cardiology
|
September 2, 1998
Predictors of fluoroscopy time and estimated radiation exposure during radiofrequency catheter ablation procedures
L S Rosenthal, M Mahesh, T J Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies
S B Maron, R-H Xu, Z A Wainberg, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
March 9, 2022
Modified urine typing to enhance clinical management in kidney transplant patients with unknown donor human leukocyte antigen typing: abridged secondary publication
J C Y Ho, Y H Yu, L C W Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
K Muro, F Lordick, T Tsushima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
K Muro, E Van Cutsem, Y Narita, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
W P Yong, B C Goh, R A Soo, et al.
The American Journal of Cardiology
|
September 2, 1998
Predictors of fluoroscopy time and estimated radiation exposure during radiofrequency catheter ablation procedures
L S Rosenthal, M Mahesh, T J Beck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies
S B Maron, R-H Xu, Z A Wainberg, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
March 9, 2022
Modified urine typing to enhance clinical management in kidney transplant patients with unknown donor human leukocyte antigen typing: abridged secondary publication
J C Y Ho, Y H Yu, L C W Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
K Muro, F Lordick, T Tsushima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2018
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
K Muro, E Van Cutsem, Y Narita, et al.
Page
of 9